Related Experiment Video
Updated: Feb 10, 2026
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
Published on: August 2, 2021
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. jaburger@mdanderson.org.
Abstract:
During the past 5 years, a number of highly active novel agents, including kinase inhibitors targeting BTK or PI3Kδ, an antagonist of the antiapoptotic protein BCL-2, and new anti-CD20 monoclonal antibodies, have been added to the therapeutic armamentarium for patients with chronic lymphocytic leukaemia (CLL). In these exciting times, care is needed to optimally integrate these novel agents into the traditional treatment algorithm without overlooking or compromising the benefits of established treatments, especially chemoimmunotherapy. A more personalized approach to CLL therapy that takes into account individual risk factors, patient characteristics, and their treatment preferences is now possible. Herein, we discuss the biological basis for the novel therapeutic agents and outline not only the major advantages of these agents over traditional therapies but also their adverse effects and the rationale for continued use of older versus newer types of therapy for selected patients with CLL. We conclude by providing recommendations for an individualized therapy approach for different populations of patients with CLL.
Insights
Novel agents like kinase inhibitors and BCL-2 antagonists offer new chronic lymphocytic leukaemia (CLL) treatments. Personalized therapy integrates these with chemoimmunotherapy, considering patient factors for optimal outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic lymphocytic leukaemia (CLL) treatment has evolved with novel targeted therapies.
- Established treatments like chemoimmunotherapy remain important considerations.
Purpose of the Study:
- To review the biological basis and clinical advantages of novel CLL agents.
- To discuss adverse effects and the rationale for combining or sequencing therapies.
- To provide recommendations for personalized CLL treatment strategies.
Main Methods:
- Review of recent clinical data and biological mechanisms of novel CLL therapeutics.
- Analysis of comparative efficacy and safety profiles against traditional treatments.
- Synthesis of evidence to inform individualized treatment algorithms.
Main Results:
- Novel agents including BTK/PI3Kδ inhibitors, BCL-2 antagonists, and anti-CD20 antibodies show high activity in CLL.
- These agents offer advantages over traditional therapies but have distinct adverse effect profiles.
- Optimal integration requires careful consideration of patient-specific factors and treatment preferences.
Conclusions:
- Personalized medicine is now feasible for CLL, balancing novel and established treatments.
- Individualized approaches considering risk factors and patient characteristics are crucial.
- Recommendations are provided for tailoring therapy in diverse CLL patient populations.
More Related Videos
03:50Author Spotlight: Effectiveness of Extracorporeal Shockwave Therapy in Achilles Tendinopathy Treatment
Published on: August 2, 2024
11:37Using Sniper-Cas9 to Minimize Off-target Effects of CRISPR-Cas9 Without the Loss of On-target Activity Via Directed Evolution
Published on: February 26, 2019
Related Concept Videos
02:55The Evidence for Evolution
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:54Convergent Evolution
00:59Gene Therapy
01:24Eukaryotic Evolution
Contrary to the endosymbiont theory, the eukaryote-first hypothesis proposes that the simpler prokaryotic and...
02:31Synteny and Evolution
Around 80 million years ago, the human and mice lineages diverged from the common ancestor. During the course of evolution, the ancestral...